BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37199346)

  • 1. Brain injury after cranial radiotherapy combined with immunotherapy for brain metastases in lung cancer: a retrospective study.
    Li J; Li W; Xu S; Zhu H
    Future Oncol; 2023 Apr; 19(13):947-959. PubMed ID: 37199346
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
    Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rationale and toxicity of combined cranial radiotherapy and immune checkpoint inhibitors in non-small cell lung cancer.
    Chen Y; Zhuang H; Wang J
    Asia Pac J Clin Oncol; 2022 Jun; 18(3):165-170. PubMed ID: 32129944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study.
    Lehrer EJ; Gurewitz J; Bernstein K; Patel D; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Malouff TD; Ruiz-Garcia H; Patel S; Bonney PA; Hwang L; Yu C; Zada G; Mathieu D; Trudel C; Prasad RN; Palmer JD; Jones BM; Sharma S; Fakhoury KR; Rusthoven CG; Deibert CP; Picozzi P; Franzini A; Attuati L; Lee CC; Yang HC; Ahluwalia MS; Sheehan JP; Trifiletti DM
    Cancer; 2022 Apr; 128(7):1429-1438. PubMed ID: 35077586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy.
    Weingarten N; Kruser TJ; Bloch O
    Clin Neurol Neurosurg; 2019 Apr; 179():14-18. PubMed ID: 30784894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
    Enright TL; Witt JS; Burr AR; Yadav P; Leal T; Baschnagel AM
    Clin Lung Cancer; 2021 Mar; 22(2):110-119. PubMed ID: 33281062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of radiation necrosis after hypofractionated stereotactic radiotherapy (HFSRT) for brain metastases: a single center retrospective study.
    Di Perri D; Tanguy R; Malet C; Robert A; Sunyach MP
    J Neurooncol; 2020 Sep; 149(3):447-453. PubMed ID: 32979130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?
    Colaco RJ; Martin P; Kluger HM; Yu JB; Chiang VL
    J Neurosurg; 2016 Jul; 125(1):17-23. PubMed ID: 26544782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer.
    Wang Y; Zhang T; Wang J; Zhou Z; Liu W; Xiao Z; Deng L; Feng Q; Wang X; Lv J; Ma X; Xue Q; Wang J; Wang Z; Bi N
    Int J Radiat Oncol Biol Phys; 2023 Jul; 116(3):590-600. PubMed ID: 36623605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang Y; Deng L; Yang Y; Zhang T; Wu Y; Wang L; Bi N
    Clin Lung Cancer; 2022 Mar; 23(2):95-107. PubMed ID: 34284948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer.
    Ge XH; Lin Q; Ren XC; Liu YE; Chen XJ; Wang DY; Wang YQ; Cao B; Li ZG; Liu ML
    Radiat Oncol; 2013 Oct; 8():238. PubMed ID: 24125485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging-defined necrosis after treatment with single-fraction stereotactic radiosurgery and immune checkpoint inhibitors and its potential association with improved outcomes in patients with brain metastases: an international multicenter study of 697 patients.
    Lehrer EJ; Ahluwalia MS; Gurewitz J; Bernstein K; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Fakhoury KR; Rusthoven CG; Mathieu D; Trudel C; Malouff TD; Ruiz-Garcia H; Bonney P; Hwang L; Yu C; Zada G; Patel S; Deibert CP; Picozzi P; Franzini A; Attuati L; Prasad RN; Raval RR; Palmer JD; Lee CC; Yang HC; Jones BM; Green S; Sheehan JP; Trifiletti DM
    J Neurosurg; 2023 May; 138(5):1178-1187. PubMed ID: 36115055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases.
    Chang J; Jing X; Hua Y; Geng K; Li R; Lu S; Zhu H; Zhang Y
    J Cancer Res Clin Oncol; 2023 May; 149(5):1825-1833. PubMed ID: 35737093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation-induced enterocolitis after combination therapy with palliative radiotherapy and immune checkpoint inhibitors in patients with metastatic lung cancer.
    Makita K; Hamamoto Y; Kanzaki H; Nagasaki K; Sugawara Y; Ninomiya T; Harada D; Kozuki T
    Exp Ther Med; 2022 May; 23(5):336. PubMed ID: 35401794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of brain metastases from lung cancer in the era of immunotherapy: a review of the literature.
    Veccia A; Kinspergher S; Dipasquale M; Caffo O
    Future Oncol; 2021 Feb; 17(5):597-609. PubMed ID: 33401981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy combined with cranial radiotherapy for driver-negative non-small-cell lung cancer brain metastases: a retrospective study.
    Lu S; Guo X; Yang Z; Sun Y; Niu J; Jing X; Zhu H
    Future Oncol; 2024 Apr; ():. PubMed ID: 38591950
    [No Abstract]   [Full Text] [Related]  

  • 17. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
    Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
    Front Immunol; 2022; 13():875488. PubMed ID: 35693805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors.
    Sneed PK; Mendez J; Vemer-van den Hoek JG; Seymour ZA; Ma L; Molinaro AM; Fogh SE; Nakamura JL; McDermott MW
    J Neurosurg; 2015 Aug; 123(2):373-86. PubMed ID: 25978710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Immune Checkpoint Inhibition vs Chemotherapy in Combination With Radiation Therapy Among Patients With Non-Small Cell Lung Cancer and Brain Metastasis Undergoing Neurosurgical Resection.
    Wasilewski D; Radke J; Xu R; Raspe M; Trelinska-Finger A; Rosenstock T; Poeser P; Schumann E; Lindner J; Heppner F; Kaul D; Suttorp N; Vajkoczy P; Frost N; Onken J
    JAMA Netw Open; 2022 Apr; 5(4):e229553. PubMed ID: 35486401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors.
    Lee JH; Chen HY; Hsu FM; Chen JS; Liao WY; Shih JY; Yu CJ; Chen KY; Tsai TH; Yang JC
    Oncologist; 2019 Dec; 24(12):e1417-e1425. PubMed ID: 31127020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.